A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC)
<b>Background</b>: Extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC) represents a major global public health challenge due to its ability to cause diverse clinical infections, including urinary tract infections, bacteremia, neonatal meningitis, and sepsis. The growi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/4/362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <b>Background</b>: Extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC) represents a major global public health challenge due to its ability to cause diverse clinical infections, including urinary tract infections, bacteremia, neonatal meningitis, and sepsis. The growing prevalence of multidrug-resistant (MDR) ExPEC strains, which rapidly erode antibiotic efficacy, underscores vaccine development as a critical priority. Bioconjugate vaccines have emerged as a promising approach to mitigate ExPEC-associated infections. <b>Methods and Results</b>: In this study, we utilized protein glycan coupling technology (PGCT) based on oligosaccharyltransferase (OST) PglL to engineer a tetravalent bioconjugate vaccine targeting four predominant ExPEC serotypes (O1, O2, O6, and O25). We conducted a series of experiments to demonstrate the efficacy of the conjugate vaccine in eliciting humoral immune responses and inducing the production of specific antibodies against <i>Escherichia coli</i> O1, O2, O6, or O25 serotypes. <b>Conclusions</b>: This work establishes the first application of the <i>O</i>-linked PGCT system for engineering bioconjugate vaccines against ExPEC infections. |
|---|---|
| ISSN: | 2076-393X |